QUOTE AND NEWS
FiercePharma  Apr 2  Comment 
It hasn't been easy being Amarin over the last several months. The Irish drugmaker slammed into one obstacle after another. Read more from FiercePharmaMarketing>>
FierceBiotech  Apr 2  Comment 
After a rough go with the FDA sent its shares spiraling downward, Amarin has at last found a partner to help commercialize its fish-oil-derived pill for high triglycerides.
SeekingAlpha  Apr 1  Comment 
ByQuoth the Raven: Amarin (AMRN) had fallen off of my radar. After failing to convince the FDA to see things its way with regards to the ANCHOR indication for its sole drug, Vascepa, I pretty much stopped paying attention to the company. There...
SeekingAlpha  Apr 1  Comment 
ByElephant Analytics: Amarin (AMRN) has recently shown some modest improvement in Vascepa prescription numbers, reaching around 3,000 NRx per week again for the first time since October. This improvement comes despite Amarin cutting its salesforce...
StreetInsider.com  Mar 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amarin+%28AMRN%29%2C+Kowa+Pharma+Enter+co-Promotion+Agreement+for+Vascepa+in+the+U.S./9333758.html for the full story.
TheStreet.com  Mar 21  Comment 
NEW YORK (TheStreet) -- Let's open this week's Biotech Stock Mailbag with a question from Andy W.: Is it possible that a Big Pharma might want to buy Amarin even more now so they could move to Ireland for the lower taxes? "Inversion" -- the...
FiercePharma  Mar 5  Comment 
Amarin's lawyers were just in court last week suing the FDA for limiting the exclusivity it granted the drugmaker's fish oil pill Vascepa. But the Irish drugmaker hustled them back to court Tuesday, this time to sue AzstraZeneca, which is awaiting...
StreetInsider.com  Mar 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amarin+%28AMRN%29+Files+Patent+Suit+Against+AstraZeneca+%28AZN%29%2C+Subsidiary/9240590.html for the full story.
FiercePharma  Feb 28  Comment 
Amarin, which has faced a series of setbacks getting its fish oil pill to market, is lashing out at the FDA for some of its problems, Bloomberg reports.
SeekingAlpha  Feb 28  Comment 
Amarin (AMRN) Q4 2013 Earnings Call February 27, 2014 4:30 pm ET Executives Joseph Bruno John F. Thero - Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Assistant Secretary and Director ...





 



References

This is a test No its not

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki